Table 2.

Details of the Studies Included in the Systematic Review. (T = length of time monitored; OS_C = raw overall survival rate; OS_A = adjusted overall survival rate; DFS_C = raw disease-free survival rate; DFS_A = adjusted disease-free survival rate; RFS_C = raw recurrence-free survival rate; RFS_A = adjusted recurrence-free survival rate).

AUTHOR	YEAR	Technique	Cutoff over-expression	N	T(YEARS)	OS_C 95% CI	OS_A 95% CI	DFS_C/RFS_C 95% CI	DFS_A/ RFS_A 95% CI
Kurihara_2016	2016	IHC	− → < 80% Mean nuclear positivity + → ≥ 80% Mean nuclear positivity	301	4.4	0.48(0.29–0.77)
Benard_2014	2014	IHC	− → ≤ median % of nuclear positivity + → > median % of nuclear positivity	247	8.6	0.74(0.54–1.03)	0.84(0.60–1.18)	0.64(0.42–0.99)	0.67(0.43–1.05)
Liu_2014	2014	q-PCR	− → ≤ median tumor/normal ratio + → > median tumor/normal ratio	82	3	—	—	4.18(2.08–8.36)	2.52(1.10–5.73)
Tamagawa_2013	2013	IHC	− → ≤ median value of H-score EZH2 (0–300) + → > median value of H-score EZH2 (0–300)	54	8	1.09(0.50–2.44)	—	—	—
Lin_2013	2013	IHC	Index value calculated as a product of the grades of the extent and intensity of staining:− → Grades 0–3 + → Grades 4–12	33	5.8	5.07(1.51–16.7)	—	—	—
Takawa_2011	2011	IHC	− → No appreciable staining in tumor cells + → Brown staining appreciable in the nucleus of tumor cells	172	5	0.39(0.19–0.83)	0.42(0.18–0.97)	—	—
Kodach_2010	2010	IHC	− → < 70% positive tumor cells + → ≥ 70% positive tumor cells	72	6.6	1.54 (0.29–8.38)	—	—	—
Wang_2010	2010	IHC	− → ≤ 30% positive tumor cells + → > 30% positive tumor cells	119	6.6	—	3.21(1.06–9.72)	—	—
Fluge_2009	2009	IHC	Index value calculated as a product of the grades of the extent and intensity of staining:− → Grades 0–3 + → Grades 4–9	409	7	—	—	1.17(0.46–2.98)	—
Mimori_2005	2005	q-PCR	− → ≤ median tumor/normal ratio + → > median tumor/normal ratio	61	8	2.17(0.93–5.07)	—	—	—